How to Verify GLP-1 and Metabolic Peptides by HPLC and MS

GLP-1-family and metabolic-research compounds are difficult to verify from a supplier name alone. Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, MOTS-c, AOD9604, and NAD+ sit in the same buyer conversation, but they do not all create the same analytical problem. HPLC answers purity and impurity-profile questions. MS answers molecular-weight identity questions. Sequence or orthogonal methods answer the cases where mass alone is not enough.

How do labs verify GLP-1 and metabolic peptides by HPLC and MS?

Labs verify GLP-1 and metabolic peptides by pairing RP-HPLC purity with MS identity evidence, then adding LC-MS/MS sequence confirmation, Edman sequencing, amino acid analysis, water, counter-ion, or impurity-profile review when the molecule is long, modified, first-time sourced, or publication-critical. NAD+ should be verified with coenzyme-appropriate identity and purity assays, not treated as a peptide.

Start with molecule class

What HPLC can and cannot prove

RP-HPLC is the first purity screen. It shows the main peak, retention time, related impurities, and relative area percent. For metabolic peptides, it is useful for comparing lot-to-lot impurity profiles and spotting shoulders, late hydrophobic impurities, or unexpected retention-time shifts.

HPLC does not prove sequence. A clean main peak can still be the wrong sequence if the molecule has the same or similar retention behavior. HPLC also does not prove mass, water content, salt form, or biological activity. Treat HPLC as one layer in the release packet, not the whole packet.

What MS can and cannot prove

ESI-MS or LC-MS confirms whether the observed molecular weight matches the theoretical molecule. This is essential for Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, MOTS-c, and AOD9604. For long or modified molecules, the report should show how charge states were interpreted and how closely the observed mass matches theory.

Mass alone does not prove residue order. Isobaric residues, sequence permutations, D/L substitutions, and some modified sequences can pass a mass check while still being wrong for a sequence-sensitive assay. For first-lot qualification, LC-MS/MS sequence evidence or another orthogonal method may be proportionate.

When to add sequence-level evidence

Add LC-MS/MS or other sequence-level evidence when:

• The molecule is long, modified, or expensive enough that a wrong lot creates large downstream cost
• The study is receptor-binding, SAR, mechanism, or publication-critical
• A buyer is qualifying a new supplier for the first time
• Lot-to-lot retention time or impurity profile changes unexpectedly
• The peptide is being transferred to a CRO or external QA team

How Lyochem frames the release packet

Lyochem's role is analytical confidence. A metabolic-research standard should ship with a lot-specific COA, HPLC trace, MS identity report, storage condition, retest date, and method notes. Where the study requires more certainty, Lyochem can scope sequence confirmation, impurity-profile explanation, or custom analytical work before the buyer commits to scale.